KR20190135839A - A composition for preventing or treating atopic dermatitis comprising the extract of corn silk - Google Patents

Abstract

The present invention relates to: a pharmaceutical composition for the prevention or treatment of atopic dermatitis by including a corn silk extract or a fraction thereof; a method of treating atopic dermatitis including a step of administering the pharmaceutical composition to a subject; a food composition for alleviating atopic dermatitis by including a corn silk extract or a fraction thereof; a quasi-drug composition for the prevention or alleviation of atopic dermatitis by including a corn silk extract or a fraction thereof; and a cosmetic composition for the prevention or alleviation of atopic dermatitis by including a corn silk extract or a fraction thereof. The corn silk extract of the present invention can be widely used for the prevention or treatment of atopic dermatitis since the corn silk extract of the present invention not only exhibits an anti-inflammatory effect but also shows an effect of inhibiting one of the causes of atopic dermatitis.

Description

A composition for preventing or treating atopic dermatitis comprising the extract of corn silk}

The present invention relates to a composition for preventing or treating atopic dermatitis comprising a corn beard extract, and more particularly, the present invention relates to a pharmaceutical composition for preventing or treating atopic dermatitis, including a corn beard extract or a fraction thereof, to a subject. A method for the treatment of atopic dermatitis comprising the step of, atopic dermatitis improving food composition comprising a corn beard extract or fractions thereof, a quasi-medicine composition for preventing or improving atopic dermatitis comprising a corn beard extract or a fraction thereof and a corn beard extract or It relates to a cosmetic composition for the prevention or improvement of atopic dermatitis comprising a fraction thereof.

The maize ( Zea mays L.) beard is a by-product of corn and is a thread-like part that is called fruit and is called oxymibal or occidental calligraphy. In addition to fatty oils, fats, bitter glycosides, saponins, alkaloids, and maisin, these corn beards contain inositol, kryptoxanthin, pantothenic acid, vitamin C, malic acid, tartaric acid, glucose, xylan, and especially large amounts of vitamin K. It is. In addition, flavonoids, one of the components contained in the corn beard, maysin (maysin), apimeisin (apimaysin), methoxymaysin (methoxymaysin), among which is the representative substance that is the most contained in corn beard In addition, the macine has been reported to inhibit the growth of corn earworm, cytotoxic effects on tumor cell lines and radical scavenging activity. Recently, research has been published that corn beard extract has anti-oxidative activity and skin protection from UV, and a study on a method for extracting a large amount of macine and similar substances from corn beard has been reported.

Skin is the first organ to function as a physical barrier that protects the body against various environmental factors, and various environmental stimuli cause activation of the immune system. In addition, atopic dermatitis, which is one of various skin diseases, is a chronic and recurrent skin disease that commonly occurs in infants and children. Symptoms such as severe itching and skin eczema continue to worsen, relieve, and relapse due to various causes. do. The incidence of atopic dermatitis continues to increase in industrialized countries, reaching 1-5% of adults, 10-20% of infants and children, and researches are being actively conducted around the world.

Accordingly, by using various components such as immunomodulators, anti-inflammatory effects, atopy-induced signal transduction inhibitors, and the like, preparations for treating atopic dermatitis have been developed. In particular, nonsteroidal systems and steroids having excellent anti-inflammatory effects are being developed. Although active research is being conducted on the substances of the lines, atopic dermatitis is not commercialized due to various reasons such as high manufacturing cost, one-time atopic treatment effect, unchecked side effects or severe side effects. I can't do it.

On the other hand, in order to solve these drawbacks, studies are being actively conducted to develop herbal medicines having atopic therapeutic effects on natural products that have been found to have no side effects. For example, Korean Patent No. 1528135 discloses a pharmaceutical composition for preventing or treating atopic dermatitis comprising white rose petal extract or pyrogallol compound isolated therefrom as an active ingredient, and Korean Patent No. 1698869 A composition for preventing or treating atopic dermatitis comprising an extract extracted from Chinese herbal medicines, including ginseng, branch, casualty, eoseongcho, hyunggae, ginseng, rhubarb, soybean, gaza and cheonhwa flour as an active ingredient, Korean Patent No. 1814389 Korean Patent No. 1828204 discloses a cosmetology composition comprising an extract of rowan vinegar and having an inhibitory effect on antioxidant activity, anti-inflammatory and atopic induction, and Korean Patent No. 1828204 discloses cornus extract, brier extract, cypress extract, birch extract, and Yule leaf extract. An anti-atopic composition comprising is disclosed. However, while the results obtained through these natural product studies show excellent safety, there is a disadvantage that a long treatment time is required to treat atopy.

Under these circumstances, the present inventors have made intensive studies to develop a safe and more effective treatment of atopic dermatitis. As a result, corn beard extract can effectively treat atopic dermatitis and has completed the present invention. .

One object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of atopic dermatitis, comprising a corn beard extract or a fraction thereof.

It is another object of the present invention to provide a method for treating atopic dermatitis comprising administering the pharmaceutical composition to a subject suspected of atopic dermatitis, except for humans.

Yet another object of the present invention is to provide a food composition for improving atopic dermatitis, including corn beard extract or a fraction thereof.

Another object of the present invention is to provide a quasi-drug composition for the prevention or improvement of atopic dermatitis, including corn beard extract or fractions thereof.

Another object of the present invention to provide a cosmetic composition for the prevention or improvement of atopic dermatitis, including corn beard extract or fractions thereof.

The present inventors have focused on corn beards as a result of conducting studies on safe natural products to develop a formulation that can safely and effectively treat atopic dermatitis.

In order to confirm whether the corn beard extract obtained by extracting the corn beard with ethanol has an effective effect on the inflammatory disease, treatment with LPS-treated macrophages results in increased production by LPS stimulation in the macrophages. It was confirmed that corn beard extract showed the effect of reducing the levels of nitric oxide (NO) and tumor necrosis factor-α (TNF-α). Thus, the corn beard extract was to determine whether it shows an effective effect against atopic dermatitis. In other words, in the epithelial cells stimulated with IFN-γ and TNF-α, the production of inflammatory cytokines, TARC (thymus and activation regualted chemokine), is increased. This increase in the production of inflammatory cytokines is one of the causes of atopic dermatitis. Known. As a result of treating the corn beard extract to the IFN-γ and TNF-α-stimulated epithelial cells, it was confirmed that the production of TARC was reduced. As a result, the corn beard extract provided in the present invention not only suppresses inflammation, but also can suppress the causative symptoms of atopic dermatitis. Thus, it was found that the corn beard extract exhibits an effective effect in the prevention or treatment of atopic dermatitis.

As such, it has not been known that the corn beard extract has a therapeutic effect against atopic dermatitis, and was first identified by the present inventors.

One embodiment of the present invention for achieving the above object provides a pharmaceutical composition for the prevention or treatment of atopic dermatitis comprising corn beard extract or a fraction thereof.

As used herein, the term "corn silk" refers to a thread-like portion, which is called jade hair, oxalic calligraphy and the like, and wraps the fruit of corn. The cornbeard contains fat oil, fat, bitter glycosides, saponins, alkaloids, and mayin, inositol, kryptoxanthin, pantothenic acid, vitamin C, malic acid, tartaric acid, glucose, xylan, and the like, in particular a large amount of vitamin K. (Cha SM, et al., Effect of particle size on physico-chemical properties and antioxidant activity of corn silk powder.Korean J. Crop Sci. 57: 41-50 (2012)). In addition, flavonoids, one of the components contained in the corn beard, maysin (maysin), apimeisin (apimaysin), methoxymaysin (methoxymaysin), among which is the representative substance that is the most contained in corn beard It is known that these macins exhibit cytotoxic effects and radical scavenging activity against tumor cell lines (Ku KM, et al., Antioxidant activity and functional components of corn silk (Zea mays L.). 22: 323-329 (2009).

In the present invention, the corn beard may be used to purchase a commercially available, or may be used collected or grown in nature, but is not limited thereto.

As used herein, the term "extract" refers to extracts obtained by extracting and treating corn beards, dilutions or concentrates of the extracts, dried products obtained by drying the extracts, crudes or purified products of the extracts, or mixtures thereof. Extracts of all formulations that can be formed using itself and extracts.

In the present invention, the corn beard extract may be named mixed with "NICS-1" or "NICS-3".

In the corn beard extract of the present invention, the method of extracting the mixture is not particularly limited, and may be extracted according to methods commonly used in the art. Non-limiting examples of the extraction method, hot water extraction method, ultrasonic extraction method, filtration method, reflux extraction method, and the like, these may be performed alone or in combination of two or more methods.

The kind of the solvent used for the extraction in the present invention is not particularly limited, and any solvent known in the art may be used. Non-limiting examples of the extraction solvent may be water, alcohol or a mixed solvent thereof, and the like, these may be used alone or may be used in combination of one or more, specifically water may be used. When using an alcohol as a solvent, specifically, the C1-C4 alcohol can be used.

As used herein, the term "fraction" refers to the result obtained by performing fractionation to separate a specific component or a specific group of components from a mixture comprising several various components.

The fractionation method of obtaining the fraction in the present invention is not particularly limited, and may be performed according to a method commonly used in the art. Non-limiting examples of the fractionation method include a solvent fractionation method performed by treating various solvents, an ultrafiltration fractionation method performed through an ultrafiltration membrane having a constant molecular weight cut-off value, and various chromatography (size, charge, hydrophobicity). Or chromatographed fractions), and combinations thereof, which are prepared for separation according to affinity. Specifically, a method of obtaining a fraction from the extract by treating a predetermined solvent with an extract obtained by extracting the corn beard of the present invention.

The kind of the fractionation solvent used to obtain the fraction in the present invention is not particularly limited, and any solvent known in the art may be used. Non-limiting examples of the fractionation solvents include polar solvents such as water and alcohols having 1 to 4 carbon atoms; Nonpolar solvents such as hexane, ethyl acetate, chloroform and dichloromethane; Or a mixed solvent thereof. These may be used alone or in combination of one or more, but are not limited thereto.

In addition, the extract or fraction may be prepared and used in the form of a dry powder after extraction, but is not limited thereto.

As used herein, the term "Atopic dermatitis (AD)" is a kind of autoimmune skin disease, and means a skin disease accompanied by swelling of the skin, eczema and itching. Although it is known that both environmental and genetic factors are involved in the development of atopic dermatitis, the exact pathogenesis has not been elucidated. In the present invention, the atopic dermatitis may be named in combination with "AD".

As used herein, the term "prevention" refers to any action that inhibits or delays atopic dermatitis by administration of a composition comprising the extract.

As used herein, the term "treatment" refers to any action in which the symptoms of atopic dermatitis improve or benefit altered by administration of a composition comprising the extract.

According to one embodiment of the present invention, corn beard extracts (NICS-1 and NICS-3) of the present invention did not show cytotoxicity in macrophages (RAW 264.7 cells) and epithelial cells (HaCaT cells), macrophages (RAW 264.7 cells), the effect of LPS stimulation on NO production was significantly increased in the LPS alone treatment group compared to the non-treated group, but corn salt extract (NICS-1 and NICS-3) In the treated group it was confirmed that the NO production decreases in a concentration-dependent manner (Fig. 1). In addition, as a result of analyzing the effect of the corn beard extract (NICS-1 and NICS-3) of the present invention based on the amount of TNF-α produced in LPS-stimulated macrophages (RAW 264.7 cells), corn beard extract (NICS -1 and NICS-3) inhibited TNF-α secretion in RAW 264.7 cells (FIG. 2). Finally, the corn beard extract (NICS-1 and NICS-3) was confirmed to exhibit the effect of inhibiting TARC production in epithelial cells HaCaT cells (Fig. 3).

Inflammatory cytokines produced excessively in epithelial cells are known to be one of the causes of atopic dermatitis. From the above results, it can be seen that the corn beard extract of the present invention has a prophylactic or therapeutic effect of atopic dermatitis.

The pharmaceutical composition of the present invention may include 0.001 to 80, specifically 0.001 to 70, more specifically 0.001 to 60% by weight based on the total weight of the composition, but is not limited thereto.

In addition, the pharmaceutical composition may further comprise a pharmaceutically acceptable carrier, excipient or diluent commonly used in the manufacture of the pharmaceutical composition, the carrier may comprise a non-naturally occuring carrier (carrier) have. The carriers, excipients and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline Cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.

In addition, the pharmaceutical compositions are tablets, pills, powders, granules, capsules, suspensions, solvents, emulsions, syrups, sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, transdermals, respectively, according to conventional methods. It can be formulated in the form of absorbents, gels, lotions, ointments, creams, patches, cataplasms, pastes, sprays, skin emulsions, skin suspensions, transdermal patches, drug containing bandages or suppositories. Specifically, when formulated, it may be prepared using diluents or excipients such as fillers, weights, binders, wetting agents, disintegrating agents, surfactants, etc. which are commonly used. Solid form preparations for oral administration include, but are not limited to, tablets, pills, powders, granules, capsules, and the like. Such solid preparations may be prepared by mixing at least one excipient such as starch, calcium carbonate, sucrose, lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate, talc, and the like can also be used. It may be prepared by adding various excipients such as humectants, sweeteners, fragrances, preservatives and the like in addition to liquids or liquid paraffin for oral use. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized formulations and suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate and the like can be used. As the base of the suppository, utopsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.

Another embodiment of the present invention provides a method for treating atopic dermatitis comprising administering the pharmaceutical composition to a subject suspected of atopic dermatitis, except for humans.

As used herein, the term "administration" refers to the act of introducing a composition comprising said extract to a subject in an appropriate manner.

As used herein, the term "individual" means all animals, such as rats, mice, and livestock, including humans who may or may develop atopic dermatitis. As a specific example, it may be a mammal including a human.

The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. The term "pharmaceutically effective amount" means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and an effective dose level may include the type and severity of the individual, age, sex, activity of the drug, Sensitivity to drug, time of administration, route of administration and rate of release, duration of treatment, factors including concurrent use of drugs, and other factors well known in the medical arts. For example, the corn beard extract may be administered at a dose of 0.01 to 500 mg / kg, specifically, at a dose of 10 to 100 mg / kg, and the administration may be administered once or several times a day.

The pharmaceutical composition may be administered as a separate therapeutic agent or in combination with other therapeutic agents and may be administered sequentially or simultaneously with conventional therapeutic agents. And single or multiple administrations. Taking all of the above factors into consideration, it is important to administer an amount that can obtain the maximum effect in a minimum amount without side effects, and can be easily determined by those skilled in the art.

In addition, the pharmaceutical composition may be administered orally or parenterally (eg, applied intravenously, subcutaneously, intraperitoneally, or topically) according to a desired method, and the dosage is based on the condition and weight of the patient, and the degree of disease. Depending on the drug form, route of administration, and time, it may be appropriately selected by those skilled in the art.

Another embodiment of the present invention provides a food composition for improving atopic dermatitis comprising a corn beard extract or a fraction thereof.

At this time, the definition of the corn beard, extract, fraction and atopic dermatitis are as described above.

As used herein, the term "improvement" means any action that at least reduces the parameters associated with the condition to be treated by administration of a composition comprising said extract, eg, the extent of symptoms.

The term "food" of the present invention, meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, drinks, tea, drinks, alcoholic beverages , Vitamin complexes, nutraceuticals and health foods, and includes all foods in the usual sense.

Since the food composition of the present invention is derived from a daily ingestible corn beard, a high atopic dermatitis improvement effect can be expected, it can be very useful for health promotion purposes.

The functional food (functional food) is the same term as a food for special health use (Food for special health use, FoSHU), in addition to the nutritional supply, the processed food, medical effect is highly effective to appear bioregulatory function Means food. Here, the term "function (sex)" refers to obtaining a useful effect for health purposes such as nutrient control or physiological action on the structure and function of the human body. The food of the present invention can be prepared by a method commonly used in the art, and the preparation can be prepared by adding the raw materials and ingredients commonly added in the art. In addition, the formulation of the food may be prepared without limitation as long as the formulation is recognized as food.

Food composition of the present invention can be prepared in a variety of dosage forms, unlike the general medicine has the advantage that there are no side effects that can occur when taking long-term use of the drug as a natural product, and because the portability is excellent, The food of the present invention can be taken as an adjuvant for enhancing the amelioration effect of atopic dermatitis.

The health food refers to foods having active health maintenance or promotion effect as compared to general foods, and the health supplement food refers to foods for health supplement purposes. In some cases, the terms nutraceutical, health food, dietary supplement are used.

Specifically, the health functional food is a food prepared by adding the compound of the present invention to food materials such as beverages, teas, spices, gums, confections, or the like, encapsulated, powdered, suspensions, etc. Means to bring effect, but unlike the general medicine has the advantage that there is no side effect that can occur when taking a long-term use of the drug as a raw material.

The food composition may further include a physiologically acceptable carrier, and the type of carrier is not particularly limited and may be any carrier that is commonly used in the art.

In addition, the food composition may include additional ingredients that are commonly used in food compositions to improve the smell, taste, time and the like. For example, it may include vitamins A, C, D, E, B1, B2, B6, B12, niacin, biotin, folate, panthotenic acid, and the like. In addition, minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn), copper (Cu) and chromium (Cr); And amino acids such as lysine, tryptophan, cysteine, valine and the like.

In addition, the food composition is a preservative (potassium sorbate, sodium benzoate, salicylic acid, sodium dehydroacetic acid, etc.), fungicides (bleaching powder and highly bleaching powder, sodium hypochlorite, etc.), antioxidants (butylhydroxyanisol (BHA), butylhydride) Oxytoluene (BHT), etc.), colorants (such as tar pigments), colorants (sodium nitrite, sodium nitrite, etc.), bleach (sodium sulfite), seasonings (such as MSG glutamate), sweeteners (ducin, cyclate, saccharin Foods such as sodium, etc.), fragrances (vanillin, lactones, etc.), swelling agents (alum, potassium D-tartrate, etc.), reinforcing agents, emulsifiers, thickeners (foils), coatings, gum herbicides, foam inhibitors, solvents, modifiers, etc. It may include food additives. The additive may be selected according to the type of food and used in an appropriate amount.

An example of the food composition of the present invention may be used as a health beverage composition, in which case it may contain various flavors or natural carbohydrates and the like as additional ingredients, such as a general beverage. The above-mentioned natural carbohydrates include monosaccharides such as glucose and fructose; Disaccharides such as maltose and sucrose; Polysaccharides such as dextrin, cyclodextrin; Sugar alcohols such as xylitol, sorbitol, and erythritol. Sweeteners include natural sweeteners such as taumartin, stevia extract; Synthetic sweeteners such as saccharin and aspartame; The ratio of the natural carbohydrate may be generally about 0.01 to 0.04 g, specifically about 0.02 to 0.03 g per 100 ml of the health beverage composition of the present invention.

In addition to the above, the health beverage composition includes various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid, salts of pectic acid, alginic acid, salts of alginic acid, organic acids, protective colloid thickeners, pH regulators, stabilizers, preservatives, glycerin, Alcohol or carbonation agent and the like. Others may contain fruit flesh for the production of natural fruit juices, fruit juice drinks, or vegetable drinks. These components can be used independently or in combination. The ratio of such additives is not critical, but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the health beverage composition of the present invention.

Another embodiment of the present invention provides a quasi-drug composition for the prevention or amelioration of atopic dermatitis comprising a corn beard extract or a fraction thereof.

At this time, the definition of corn beard, extract, fraction, atopic dermatitis, prevention and improvement is as described above.

As used herein, the term "quasi drug" refers to a fiber, rubber product or the like used for treating, alleviating, treating or preventing a disease of a human or animal, has a weak action on the human body or does not directly act on the human body, Or non-machinery and the like, or any of the agents used for sterilization, insecticide and similar purposes for the prevention of infection, for the purpose of diagnosing, treating, reducing, treating or preventing human or animal diseases. Among articles to be used, which are not instruments, machines or devices, and articles which are used for the purpose of pharmacologically affecting the structure and function of a person or animal, except those which are not instruments, machines or devices. Also includes supplies.

Corn beard extract of the present invention, when added to the quasi-drug composition for the purpose of preventing or improving atopy, the extract can be added as it is, or can be used in combination with other quasi-drug components, can be suitably used in accordance with conventional methods. The mixed amount of the active ingredient may be suitably determined depending on the purpose of use (prevention, health or therapeutic treatment).

The quasi-drug composition is not particularly limited, but includes personal hygiene products, external skin preparations, antiseptic cleaning agents, shower foams, wet wipes, detergent soaps, hand washes, masks, or ointments. The external skin preparations are not particularly limited thereto, and specifically, may be manufactured and used in the form of an ointment, lotion, spray, patch, cream, powder, suspension, gel or gel. The personal hygiene product is not particularly limited thereto, but may be specifically a soap, a wet tissue, a tissue, a shampoo, a toothpaste, a hair care product, an air freshener gel or a cleaning gel.

Another embodiment of the present invention provides a cosmetic composition for the prevention or amelioration of atopic dermatitis comprising a corn beard extract or a fraction thereof.

At this time, the definition of corn beard, extract, fraction, atopic dermatitis, prevention and improvement is as described above.

The corn beard extract may include the extract in a ratio of 0.1% to 20% by weight based on the total weight of the composition, similar to the pharmaceutical composition. Specifically, the composition is included in the ratio of 0.1 wt% to 5 wt%, more specifically 0.4 to 0.6 wt%, and more specifically 0.5 wt%, based on the total weight of the composition, but is not limited thereto.

Components included in the cosmetic composition of the present invention includes components commonly used in cosmetic compositions in addition to the extract, for example, water, surfactants, moisturizers, lower alcohols, chelating agents, fungicides, antioxidants, preservatives, pigments And one or more additives selected from the group consisting of fragrances.

In addition, the cosmetic composition may be prepared in any of the formulations conventionally prepared, for example solutions, emulsions, suspensions, pastes, creams, lotions, gels, powders, sprays, surfactant-containing cleansing, oils, soaps, It may be formulated as a liquid detergent, bath, foundation, makeup base, essence, lotion, foam, pack, flexible water, sunscreen cream or sun oil, but is not limited thereto.

When the formulation of the present invention is a solution or emulsion, a solvent, solubilizer or emulsifier is used as the carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 Fatty acid esters of, 3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan.

When the formulation of the present invention is a suspension, a liquid diluent such as water, ethanol or propylene glycol, suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, and microcrystals are used as carrier components. Castle cellulose, aluminum metahydroxy, bentonite, tracant and the like can be used.

When the formulation of the present invention is a paste, cream or gel, animal oils, vegetable oils, waxes, paraffins, starches, trachants, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicas, talc or zinc oxide may be used as carrier components. Can be.

When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used, in particular in the case of a spray, additionally chlorofluorohydrocarbon, propane Propellant such as butane or dimethyl ether.

When the formulation of the present invention is a surfactant-containing cleansing, the carrier component is an aliphatic alcohol sulfate, an aliphatic alcohol ether sulfate, a sulfosuccinic acid monoester, an isethionate, an imidazolinium derivative, a methyltaurate, a sarcosinate, a fatty acid amide. Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.

In addition, the components included in the cosmetic composition may be included in an amount generally used in the field of dermatology.

Corn beard extract of the present invention not only exhibits an anti-inflammatory effect, it was confirmed that exhibits the effect of inhibiting one of the causes of atopic dermatitis, corn beard extract of the present invention can be widely used for the prevention or treatment of atopic dermatitis There will be.

1 is a graph showing the results of comparing the effect of the corn beard extract on the NO production in LPS-treated macrophages (Raw 264.7).
Figure 2 is a graph showing the results of comparing the effect of corn beard extract on the TNF-α production in LPS treated macrophages (Raw 264.7).
Figure 3 is a graph showing the results of comparing the effect of corn beard extract on TARC production in epithelial cells (HaCaT cells) treated with INF-r and TNF-α.

Hereinafter, the present invention will be described in more detail with reference to Examples. However, these examples are for illustrative purposes only and the scope of the present invention is not limited to these examples.

Example  1: Corn Beard Extract ( NICS -One, NICS -3) manufacturing

Corn beard samples were used to collect corn beards of 'Gwangpyeongok', which was grown and produced by the Rural Development Administration.

Immediately after taking the sample, cut it into a size of about 5-10 cm, and add 2000 ml of alcohol (Pretanol A, Reagents Duksan, Gyeonggi-do, Korea) 2000 ml to 1 kg of shredded corn beard to shine in direct sunlight. Extraction was carried out at a temperature of 25 ° C. for 9 days. The extract obtained therefrom was subjected to primary filtration with cotton wool and then No. Secondary filtrate was filtered with 3 filter paper and concentrated under reduced pressure to obtain a crude corn beard extract. The obtained corn beard crude extract was injected into a column packed with C18 (Preparative C18 reverse phase bulk packing material, 125, 55-105 μm, Waters, Milford, Mass.) Powder and ethanol weight% at the initial composition of ultra pure weight%. The mobile phase was poured by the gradient method of bay to obtain corn beard extract (NICS-1). Corn beard extract obtained through the above process (NICS-1) is re-injected into the C18 column to obtain a high purity Meisin to take an aliquot containing a large amount of Meisin and concentrated under reduced pressure again and high purity Cornbeard extract (NICS-3) was obtained comprising the Meisin solids.

Example  2: Cell Culture and Cell Viability Measurement

RAW 264.7 cells (mouse macrophage cells (ATCC) and HaCaT cells (human keratinocytes, HaCaT, ATCC) were 10% FBS, penicillin (100 U / ml) and streptomycin (100 μg / ml) at 37 ° C and 5% CO2 conditions. This was incubated with the added DMEM medium. When the culture was fully propagated at 3 days intervals, 1 ml of 0.25% trypsin-EDTA solution was added thereto, and then treated at room temperature for 1 minute, and then the cells were detached and subcultured. The detached cells were suspended in 10 ml of DMEM medium added with 10% FBS, and then transferred to a new culture vessel and cultured in a CO ₂ incubator (37 ° C., 5% CO ₂ ) at a split ratio of 1: 2.

Cell viability was measured to determine whether the two prepared corn beard extracts (NICS-1, NICS-3) show cytotoxicity. Cell viability was measured by diluting the WST-1 reaction solution (cell proliferation reagent WST-1, Roche, Bern, Swiss) 1/10 in DMEM medium and processing 100 μl of each well for 1 hour and then reacting at 450 nm. Absorbance was measured. As a result, it was confirmed that both extracts (NICS-1, NICS-3) did not show cytotoxicity.

Example  3: Anti-inflammatory effect through evaluation of NO production inhibition

NO is known to play an important role in various diseases such as inflammatory reactions, tumorigenicity, hypertension, diabetes and dermatitis. In general, when stimulated by LPS in macrophages, it is known to induce an inflammatory response by producing a large amount of inflammatory mediator NO. To determine the effect of NICS-1 and NICS-3 on RAW 264.7 cells on NO production, sample concentrations of 10, 50, and 100 μg / ml were stimulated with LPS (1 μg / ml) 30 minutes after treatment. After 24 hours incubation was confirmed the NO production amount.

Specifically, Raw 264.7 cells of 5 × 10 ⁴ cells per well were dispensed into 96-well plates and cultured for 18 hours. After incubation, the samples were treated according to the concentration, and after 30 minutes, the samples were incubated for 24 hours by treating LPS (lipopolysaccharide), which is an inflammatory induction factor. The amount of generated NO was measured in the form of NO ₂ ⁻ present in the cell culture using a grease reagent. After 100 μl of the cell culture supernatant and 100 μl of the grease reagent were reacted at room temperature for 10 minutes, the absorbance was measured at 540 nm. At this time, the NO concentration of the culture solution was compared with a standard of sodium nitrite (standard) (FIG. 1).

1 is a graph showing the results of comparing the effect of the corn beard extract on the NO production in LPS-treated macrophages (Raw 264.7).

As shown in FIG. 1, the NO production was significantly increased in the LPS treatment group compared with the non-treatment group, but in the group treated with the corn salt extract (NICS-1 and NICS-3), the NO production decreased in a concentration-dependent manner. .

Specifically, the NO production amount was 49.43 nM when LPS alone was treated, but when NICS-1, which was purified once in the extract, was simultaneously treated at 100 ㎍ / mL, the NOS was decreased by more than 50% to 21.43 nM. In addition, the NICS-3, which was purified twice in the corn beard extract, showed a significant decrease in NO production at the concentrations of 26.25 nM and 3.60 nM, respectively, when 50 μg / ml and 100 μg / ml were treated. In other words, the inhibition of NO production by LPS was found to have a better inhibitory effect when NICS-3 was treated than NICS-1.

Example  4: TNF anti-inflammatory effect through -α production inhibition evaluation

TNF-α is a major mediator of the LPS response and plays a key role in the initiation and maintenance of inflammation, resulting in increased expression in inflammatory lesions, particularly in chronic inflammatory diseases. These TNF-α intensifies inflammation through mechanisms that bind TNF-α receptors of themselves and other macrophages through endocrine and exocrine as ligands to activate various inflammatory mediating transcription factors to express TNF-α. Therefore, corn beard extract was analyzed for TNF-α secretion effect in RAW 264.7 cells.

Specifically, 1 × 10 ⁶ cells per well of Raw 264.7 cells were dispensed in a 48 well plate and cultured for 24 hours. After incubation, the cells were starved for 12 hours and then cultured for 24 hours by treating LPS 1 ㎍ / mL and each corn beard extract (0, 10, 50, 100 ㎍ / mL) alone or mixed. The cultured cells were harvested and the amount of TNF-α was measured by ELISA. In addition, the cells attached to the bottom was washed with PBS, and then lysed with 1N sodium hydroxide (NaOH) to measure the total protein amount to determine the amount of TNF-α production for a certain protein. At this time, the amount of each TNF-α and the amount of protein was measured according to the correction line (Fig. 2).

Figure 2 is a graph showing the results of comparing the effect of corn beard extract on the TNF-α production in LPS treated macrophages (Raw 264.7).

As shown in Figure 2, LPS alone treatment showed a high TNF-α production of 3401.09 pg / ㎖, but when treated with corn beard extract (NICS-1 and NICS-3), respectively, 1862.76 and 100 ㎍ / ㎖ It was inhibited at 1364.25 pg / ml. Particularly, in the case of NICS-3, the production amount was confirmed to be 2621.80 pg / ml in the 10 ㎍ / ml treatment and 2195.97 pg / ml in the 50 ㎍ / ml treatment.

From the above results, it was found that corn beard extract (NICS-1 and NICS-3) is involved in anti-inflammatory function by inhibiting TNF-α secretion in RAW 264.7 cells.

Example  5: atopic dermatitis improvement effect

The effects of corn beard extract on the production of thymus and activation regualted chemokine (TARC), a type of inflammatory cytokine (Th2 chemokine) produced by epithelial cells (HaCaT cells), were analyzed.

Specifically, HaCaT cells, which are epithelial cells, were divided into 48 well plates at 1 × 10 ⁶ cells per well and incubated for 24 hours. The medium was removed and 10 ng / ml of INF-r and 10 ng / ml of TNF-α and respective cornbeard extracts were diluted in the media at respective concentrations and then treated. After incubation for 24 hours, the culture medium was taken, and the TARC secretion was measured using a Human TARC immunoassay kit (Immunoassay kit, R & D systems, PDDN00).

Figure 3 is a graph showing the results of comparing the effect of corn beard extract on TARC production in epithelial cells (HaCaT cells) treated with INF-r and TNF-α.

As shown in FIG. 3, the experimental group treated with IFN-γ and TNF-α showed a significant increase in TARC production compared to the control group without any treatment, and treatment of IFN-γ and TNF-α resulted in atopy of HaCaT cells. It can be seen that effectively induced.

In addition, in the case of NICS-1, 925.3%, 580.9%, and 161.8% of TARCs were generated in comparison with the control group not treated with IFN-γ and TNF-α, which decreased in a concentration-dependent manner. In contrast, 301.5%, 1210.8%, and 924.9% of TARCs were generated, and the concentration-dependent decrease was similar to NICS-1. In other words, the corn beard extracts (NICS-1 and NICS-3) of the present invention was found to exhibit the effect of inhibiting TARC production in HaCaT cells which are epithelial cells.

From the above results, it was found that the corn beard extract of the present invention can suppress the production of inflammatory cytokines produced in epithelial cells, and thus have an effect of treating atopic dermatitis.

From the above description, those skilled in the art will appreciate that the present invention can be implemented in other specific forms without changing the technical spirit or essential features. In this regard, the embodiments described above are to be understood in all respects as illustrative and not restrictive. The scope of the present invention should be construed that all changes or modifications derived from the meaning and scope of the following claims and equivalent concepts rather than the detailed description are included in the scope of the present invention.

Claims (13)

Pharmaceutical composition for the prevention or treatment of atopic dermatitis, comprising a corn beard extract or a fraction thereof.
The method of claim 1,
The corn beard extract is to reduce the levels of nitric oxide (NO) and TNF-α (tumor necrosis factor-α) produced in macrophages stimulated with lipopolysaccharide (LPS), pharmaceutical composition for the prevention or treatment of atopic dermatitis .
The method of claim 2,
The macrophages are RAW 264.7 cells, pharmaceutical composition for the prevention or treatment of atopic dermatitis.
The method of claim 1,
The corn beard extract is to reduce the level of inflammatory cytokines produced in epithelial cells stimulated with IFN-γ (Interferon-γ) and TNF-α (tumor necrosis factor-α), for the prevention or treatment of atopic dermatitis Pharmaceutical composition.
The method of claim 4, wherein
The epithelial cells are HaCaT cells, pharmaceutical composition for the prevention or treatment of atopic dermatitis.
The method of claim 4, wherein
The inflammatory cytokine is TARC (thymus and activation regualted chemokine), pharmaceutical composition for preventing or treating atopic dermatitis.
The method of claim 1,
Wherein the extract is obtained by extracting corn beard with at least one solvent selected from the group consisting of water, alcohol having 1 to 4 carbon atoms and mixed solvents thereof, pharmaceutical composition for preventing or treating atopic dermatitis.
The method of claim 1,
The fraction is selected from the group consisting of corn beard extract water, alcohol having 1 to 4 carbon atoms, hexane (Hexane), ethyl acetate (Ethyl acetate), chloroform (Chloroform), dichloromethane and a mixed solvent thereof A pharmaceutical composition for preventing or treating atopic dermatitis, obtained by fractionation with a solvent.
The method of claim 1,
The composition is a pharmaceutical composition for the prevention or treatment of atopic dermatitis, further comprising a pharmaceutically acceptable carrier, excipient or diluent.
A method for treating atopic dermatitis, comprising administering the pharmaceutical composition of any one of claims 1 to 9 to a suspected subject of atopic dermatitis other than humans.
A food composition for improving atopic dermatitis, including corn beard extract or fractions thereof.
A quasi-drug composition for the prevention or improvement of atopic dermatitis comprising a corn beard extract or a fraction thereof.
Cosmetic composition for the prevention or improvement of atopic dermatitis, including corn beard extract or fractions thereof.

Images